Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Payables (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Payables data on record, last reported at $56.8 million in Q4 2025.

  • For Q4 2025, Payables rose 47.25% year-over-year to $56.8 million; the TTM value through Dec 2025 reached $56.8 million, up 47.25%, while the annual FY2025 figure was $56.8 million, 47.25% up from the prior year.
  • Payables reached $56.8 million in Q4 2025 per APLS's latest filing, up from $38.6 million in the prior quarter.
  • Across five years, Payables topped out at $56.8 million in Q4 2025 and bottomed at $4.2 million in Q1 2021.
  • Average Payables over 5 years is $28.9 million, with a median of $29.5 million recorded in 2023.
  • Peak YoY movement for Payables: plummeted 54.97% in 2021, then soared 203.8% in 2022.
  • A 5-year view of Payables shows it stood at $16.9 million in 2021, then skyrocketed by 120.84% to $37.3 million in 2022, then rose by 0.47% to $37.5 million in 2023, then increased by 2.81% to $38.6 million in 2024, then skyrocketed by 47.25% to $56.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $56.8 million in Q4 2025, $38.6 million in Q3 2025, and $54.2 million in Q2 2025.